by Richard Daverman, PhD
March 29, 2014 --RuiYi, a San Diego-Shanghai biotech, raised $15 million in a Series B round to develop a portfolio of mAbs that bind to GPCR targets with high specificity; Golden Meditech of Hong Kong raised $101 million by selling its stake in a China mobile phone retailer, which it will put to use in China healthcare; Mapi Pharma, an Israeli API company with R&D operations in China, filed for a $46 million IPO on NASDAQ; MicroPort Medical received CFDA approval for its third-generation drug eluting stent; Lee’s Pharma of Hong Kong and its partners will start a global Phase III trial of an immunotherapy treatment for liver cancer; Jiangsu Nhwa Pharma will spend $64 million to build an API manufacturing facility in Xuzhou; and Jiangsu SR-BioPharma has broken ground on a new facility in Taizhou’s China Medical City, where it will make its HPV vaccine. More details….
Stock Symbols: (HK: 801; TW: 910801) (HK: 853) (HK: 0950)
Help employers find you! Check out all the jobs and post your resume.
